Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with prostate adenocarcinoma (a specific type of prostate cancer) confirmed by a pathology lab within the last 2 years before joining the study — tissue samples must be reviewed by the NCI's Laboratory of Pathology, and a new biopsy may be collected if archived tissue is not available
• People whose biopsy results show a Gleason score of 7 or lower, with a primary pattern of 3 (a measure of how the cancer cells look under a microscope — confirm with trial site if unsure what this means)
• People whose cancer is classified as stage cT1C or cT2A (early, localised stages — confirm with trial site)
• Adult males aged 18 years or older
• People who are able to understand and sign a written consent form, including one that shows an understanding of "active surveillance" (a monitoring approach rather than immediate treatment) as their chosen management plan
• People who are also enrolled in a specific related NCI study called protocol 16-C-0010, which focuses on prostate cancer patient care and tissue collection

Who may not be able to join:

• People whose prostate cancer has spread to other parts of the body or has grown beyond the prostate into surrounding areas
• People who have previously had radiation treatment to the pelvic area
• People who have a bleeding disorder that is not currently stable or well-managed
• People with severely weakened immune systems, such as HIV patients with a very low CD4 count (below 200), people who have had a bone marrow transplant, or people with a condition called severe combined immunodeficiency
• People with severe haemorrhoids (grade 3 or above)
• People who have had certain prior pelvic surgeries that would make accurate imaging or biopsy difficult (confirm with trial site which surgeries apply)
• People who have previously had any treatment directed at the prostate for prostate cancer
• People who are unable to have an MRI scan, including those with an allergy or sensitivity to MRI contrast dye, or those whose kidneys are not functioning well enough to safely receive the contrast agent
• People whose MRI scan shows the cancer has spread beyond the prostate (such as into the seminal vesicles or surrounding tissue)
• People whom the trial doctors consider ineligible for any other medical reason

Important: Always verify eligibility with the trial site directly before applying.